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Abstract
Background: Activating mutations in the PIK3CA gene have been identified in a variety of human
malignancies and are commonly detected in hotspot codons located in the helical and kinase
domains in exons 9 and 20. Existing methodologies for the detection of PIK3CA mutations are time-
consuming and/or expensive. In the present study we describe the first application of a PIK3CA
SNaPshot assay to the screening of frequent mutations in these exons.
Findings: A SNaPshot assay for the simultaneous detection of four frequent PIK3CA hotspot
mutations (E542K, E545G, E545K and H1047R) has been developed and evaluated. The assay
combines multiplex PCR amplification with a multiplex primer extension assay to allow targeted
detection of all four mutations in one reaction. The method was tested using samples that had
previously been analysed for mutations by high-resolution melting analysis and sequencing. All
mutations detected were concordant and no false positive results were obtained. Sensitivity tests
showed that the SNaPshot assay could detect mutant DNA when it represents 5–10% of the total
DNA present. The application of the method to the analysis of DNAs extracted from formalin-
fixed paraffin-embedded samples was also demonstrated.
Conclusion: The SNaPshot assay described here offers a fast, sensitive, inexpensive and specific
approach to the analysis of frequent PIK3CA mutations in both fresh and archival patient samples.
Background
The phosphatidylinositol 3-kinase (PI3K) pathway plays
an important role in many cellular processes including
cell proliferation, adhesion, survival and motility. Dysreg-
ulation of this pathway has been observed in many types
of human malignancy and has commonly been associated
with genetic alterations in components of the pathway
(reviewed in [1]). Such genetic alterations include activat-
ing mutations in the PIK3CA gene encoding the p110α
subunit of class IA PI3K.
Somatic mutations of PIK3CA have now been reported in
several types of human cancer [2-13]. Although mutations
have been detected throughout the PIK3CA gene, com-
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mon mutational hotspots occur in the helical (exon 9)
and kinase (exon 20) domains with E542K, E545K and
H1047R being most frequent. Recently, mutations of
PIK3CA were also detected in epidermal nevi (EN) and
seborrheic keratoses (SK), two benign skin lesions [14].
All mutations detected in EN samples were of the E545G
type whereas SK displayed E542K, E545K and H1047R
mutations.
PCR-based screening methods (e.g. single strand confor-
mation polymorphism analysis, high resolution melting
analysis, ARMS/Scorpion assays) and direct sequencing of
PCR products have typically been applied to the identifi-
cation of PIK3CA mutations [5,13,15,16]. However, with
large numbers of samples, these approaches are time con-
suming and/or expensive. As specific inhibitors for
PIK3CA become available it will be essential to be able to
screen patient samples rapidly. Primer extension (SNaP-
shot) assays have been developed for several genes with
common mutations, e.g. FGFR3  and BRCA1/2  [17,18].
The SNaPshot method offers a specific, sensitive, inexpen-
sive and rapid alternative to screening for mutations and
subsequent confirmation by sequencing. Here we
describe a SNaPshot assay for the simultaneous detection
of the PIK3CA  mutations, E542K, E545G, E545K and
H1047R.
Methods
Samples and DNA extraction
Sixteen bladder tumour-derived cell lines (5637, 253J,
639V, 647V, 97-21, 97-24, 97-29, BFTC909, CAL29,
HT1197, HT1376, J82, JO'N, TCC-SUP, VMCUB1,
VMCUB3), 175 fresh-frozen bladder tumour tissue sam-
ples and 5 formalin-fixed paraffin-embedded seborrheic
keratosis samples were used. All DNAs were extracted
using a QIAmp DNA kit.
Multiplex PCR primers and SNaPshot probes
Multiplex PCR primers and SNaPshot probes were
selected using a web-based oligonucleotide check tool
http://depts.washington.edu/bakerpg/primertemp/
primermelttemp.html so that they had matching melting
temperatures of approximately 65°C. Primer sequences
were analysed for secondary structures, complementarity
and specificity. Primers were selected for amplification of
exon 9 (ex9-Fw 5'-AGTAACAGACTAGCTAGAGA-3'; ex9-
Rv 5'-ATTTTAGCACTTACCTGTGAC-3') and exon 20
(ex20-Fw 5'-GACCCTAGCCTTAGATAAAAC-3'; ex20-Rv
5'-GTGGAAGATCCAATCCATTT-3'), with the amplicons
covering hotspot codons 542, 545 and 1047. SNaPshot
probes for detection of E542K, E545G, E545K and
H1047R mutations were designed to anneal on the sense
strand immediately adjacent to the mutation site (Table
1). Each probe was synthesised with a different length of
poly(dT) tail to allow separation of SNaPshot products on
the basis of size (Table 1).
Multiplex PCR amplification
Multiplex PCR was performed in a volume of 15 μl con-
taining 1 × PCR buffer, 1.5 mM MgCl2, 0.17 mM dNTPs,
0.7 μM of each primer, 5% glycerol, 1 unit GoTaq DNA
polymerase and 20 ng of template DNA. Thermal cycler
conditions were: 95°C for 5 min, 35 cycles of 95°C for 45
sec, 60°C for 45 sec, 72°C for 45 sec and finally 10 min at
72°C. The number of cycles was increased to 45 for the
analysis of DNAs extracted from paraffin-embedded
material. Multiplex PCR products were checked for quality
and yield by running 3 μl in 2% agarose-TBE gels. The
remaining PCR products were treated with 3 units of
shrimp alkaline phosphatase and 2 units of exonuclease I
to remove excess deoxyribonucleotide triphosphates
(dNTPs) and primers, respectively.
SNaPshot analysis
SNaPshot analysis was performed using an Applied Bio-
systems SNaPshot Multiplex Kit. Reactions were per-
formed in a volume of 9 μl containing 2.5 μl of SNaPshot
Ready Multiplex Ready Reaction Mix, 1 × BigDye sequenc-
ing buffer, 1 μl of probe mix (see Table 1 for probe con-
centrations) and 1 μl of shrimp alkaline phosphatase/
exonuclease-treated multiplex PCR product. Extension
reactions were performed in a thermal cycler and con-
sisted of 35 cycles of denaturation at 95°C for 10 sec and
annealing/extension at 58.5°C for 40 sec. Labelled exten-
sion products were treated with shrimp alkaline phos-
phatase (1 unit per sample) then diluted 1 in 10. 1 μl of
the diluted extension product was mixed with 9.8 μl of
HiDi™ formamide and 0.2 μl of Genescan-120LIZ size
standard. Products were denatured at 95°C for 5 minutes
then separated using an ABI PRISM 3100 Genetic Ana-
lyzer with a 36 cm length capillary and POP-7™ polymer.
Analysis was performed using GeneMapper 3.7 Software.
Table 1: SNaPshot probes for the detection of PIK3CA mutations.
Probe Sequence (5'->3') Size (bp) Mutation Concentration
in probe mix (μM)
E542K T(19)TACACGAGATCCTCTCTCT 38 G->A 0.8
E545G T(29)TCCTCTCTCTGAAATCACTG 49 A->G 2.3
E545K T(34)ATCCTCTCTCTGAAATCACT 54 G->A 1.5
H1047R T(46)TGAAACAAATGAATGATGCAC 67 A->G 1.5BMC Research Notes 2009, 2:66 http://www.biomedcentral.com/1756-0500/2/66
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Sensitivity of the SNaPshot assay
Mixtures of bladder tumour DNAs heterozygous for
PIK3CA mutations and normal DNA were prepared to test
the sensitivity of the SNaPshot assay. 20 ng of template
DNA containing mutant DNA at final percentages of
100%, 25%, 10%, 5% or 1% was used in SNaPshot anal-
ysis.
Results and discussion
The first step of the SNaPshot assay described here
involved the design and optimisation of a multiplex PCR
reaction for the simultaneous amplification of DNA frag-
ments from exons 9 and 20. Relatively small PCR amplifi-
cation product sizes (139 bp for exon 9 and 109 bp for
exon 20) were chosen so that the assay could be applied
to the analysis of partially degraded DNA samples such as
those obtained from formalin-fixed paraffin-embedded
samples. PCR primers were initially tested in single-prod-
uct reactions prior to being used in multiplex reactions.
Similar quantities of both products were observed in mul-
tiplex PCR reactions.
The primer extension (SNaPshot) assay utilises an
Applied Biosystems SNaPshot Multiplex Kit that contains
a reaction mix of four differentially fluorescently labelled
ddNTPs, allowing the interrogation of each base at a
mutation site. When used in combination with the size-
specific PIK3CA SNaPshot probes (Table 1), it was possi-
ble to screen simultaneously for E542K, E545G, E545K
and H1047R mutations. Initially, extension reactions
were performed using equal concentrations of the probes.
Subsequently, the concentration of each probe was
adjusted to give more comparable peak heights (Table 1).
To evaluate the performance of the SNaPshot assay we
performed a blind screen of 16 bladder tumor-derived cell
line and 175 fresh-frozen primary bladder tumor DNAs
that had previously been analysed for PIK3CA mutations
in exons 9 and 20 by high-resolution melting analysis
using the LightScanner system and direct sequencing
(Platt  et al. manuscript in preparation). SNaPshot
detected heterozygous mutations in 7 cell lines (E542K n
= 1 [VMCUBI]; E545G n = 1 [253J]; E545K n = 4 [HT1197;
BFTC909; VMCUB3; TCC-SUP]; H1047R n = 1 [CAL29])
and 37 tumors, and results were 100% concordant with
the data obtained by Platt et al. A representative example
of each of the four common codon mutations detected in
the cell lines is shown in Figure 1(A–E). Peaks are colour-
coded by the Genemapper software according to the dye-
label on the incorporated ddNTP. Genotype scoring is
manual and is based on the peak colour and position rel-
ative to a set of internal size standards. Mutations in each
codon were easily identified on the basis of peak size and
colour. Slight shifts in the molecular weights of mutant
alleles were observed due to mobility differences in the
fluorophores used to detect each of the bases. However,
probes were sufficiently spaced such that these mobility
differences did not impair interpretation of the resulting
electropherograms.
We also applied the method to a panel of five DNAs
extracted from formalin-fixed paraffin-embedded sebor-
rheic keratoses. When analysing samples of this nature it
was observed that the quality of SNaPshot results
obtained was invariably linked to the intensity of the mul-
tiplex PCR products. To obtain sufficient multiplex PCR
product for SNaPshot analysis, the number of PCR ampli-
fication cycles was therefore increased to 45 for these sam-
ples. Screening revealed an E542K mutation in one of the
DNAs (Figure 1F) whilst all other samples were found to
be wildtype, confirming results obtained previously by
direct sequencing [19].
Finally, we assessed the sensitivity of the SNaPshot assay
by mixing heterozygous mutant DNA from low grade/
stage bladder tumors (that are commonly diploid or near-
diploid) with normal DNA in varying proportions. We
were able to detect mutations E542K, E545K and H1047R
when mutant DNA represented 5–10% of the total input
DNA. Figure 2 shows representative examples of results
obtained for codons E542K and E545K. As mutant DNAs
used in these experiments were heterozygous, the
observed sensitivity results equate to being able to detect
one mutant allele in a background of 39 (5%) or 19
(10%) wildtype alleles. This level of detection is compara-
ble to that reported for the FGFR3 SNaPshot assay of van
Oers et al. [17]. We were also able to achieve a 5% level of
detection for codon E545K when mutant DNAs from two
triploid bladder tumor cell lines (TCC-SUP and BFTC909)
were used (data not shown). Calling the presence of low-
level mutations is more difficult and in these cases more
than one individual should perform scoring and the assay
should be repeated to confirm that the mutations do not
represent artefacts.
It is perhaps surprising that we did not uncover extra
mutations to those detected by the LightScanner and
direct sequencing approach. Board et al. [15] reported that
conventional sequencing was unable to detect the pres-
ence of H1047R and E542K mutations when present at
<50% and <30% of the total mixture, respectively. On this
basis, the SNaPshot assay should be more sensitive than
the LightScanner and direct sequencing confirmation
approach. The high concordance of results most likely
reflects the fact that the DNAs analysed in our study were
extracted from samples consisting of >80% tumor cells.
The SNaPshot assay described in the present study repre-
sents a relatively inexpensive approach to the detection of
PIK3CA mutations. The cost of the SNaPshot MultiplexBMC Research Notes 2009, 2:66 http://www.biomedcentral.com/1756-0500/2/66
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SNaPshot detection of four common hotspot mutations in the PIK3CA gene Figure 1
SNaPshot detection of four common hotspot mutations in the PIK3CA gene. (A-E) SNaPshot results obtained from 
the analysis of bladder tumor-derived cell line DNAs illustrating (A) wildtype, (B) E542K, (C) E545G, (D) E545K and (E) 
H1047R electropherogram patterns. (F) SNaPshot detection of an E542K codon mutation in DNA extracted from a formalin-
fixed paraffin embedded seborrheic keratosis sample. Bases are represented by the following colours: A = green; C = black; G 
= blue; T = red. Orange peaks (S) represent the internal Genescan-120LIZ size standards. All DNAs were extracted using a 
QIAmp DNA kit.BMC Research Notes 2009, 2:66 http://www.biomedcentral.com/1756-0500/2/66
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Ready Reaction Mix is £1.16 per sample. In comparison a
standard sequencing reaction using BigDye Terminator
v1.1 Ready Reaction Mix costs £2.59 per sample. Methods
that employ pre-screening approaches may initially repre-
sent a cheaper alternative to mutation detection but the
subsequent requirement for sequence verification of
potential mutations significantly increases the time and
cost of these assays relative to the SNaPshot method. The
PIK3CA SNaPshot assay is less expensive than methods
which employ the use of fluorescently-labelled oligonu-
cleotide probes [15] as the probes used in the SNaPshot
assay are unlabelled primers. Pati et al. [20] compared the
SNaPshot method to pyrosequencing and biplex invader
SNP genotyping methods. The authors concluded that the
Sensitivity of the PIK3CA SNaPshot assay Figure 2
Sensitivity of the PIK3CA SNaPshot assay. SNaPshot could detect mutant PIK3CA when it represented 5% to 10% of the 
total DNA present. Representative examples for bladder tumors with (A) E542K and (B) E545K are shown.BMC Research Notes 2009, 2:66 http://www.biomedcentral.com/1756-0500/2/66
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SNaPshot assay required little optimisation and was com-
parable to these two methods but with a higher cost when
singleplex reactions were used. The authors also reported
that failed reactions were mostly associated with poor
PCR amplification. In the present study, we have designed
a robust multiplex PCR and did not observe any such reac-
tion failures. The combined multiplex PCR and SNaPshot
reaction makes it possible to screen simultaneously for
four mutations. In addition, all steps of the SNaPshot
assay are performed in 96 well plates and the method
could easily be automated for high throughput analysis.
Conclusion
A SNaPshot assay for the simultaneous screening of four
frequent PIK3CA codon mutations has been developed.
The detection of multiple mutations in a single reaction
reduces cost, amount of patient sample DNA and sample
handling required. The interpretation of results is quick
and easy and the method is flexible so that if required,
appropriately sized probes targeting additional hotspot
codons could be added to the assay. A major advantage is
the avoidance of an extra sequencing step that is a require-
ment of many pre-screening-based methods.
As specific inhibitors for PIK3CA become available, rapid
screening of patient samples for mutations will be essen-
tial. The SNaPshot assay described here can be high
throughput and is robust and objective making it suitable
for use in such a diagnostic setting.
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